Trials / Conditions / Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

12 registered clinical trials studyying Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma NCT07042438	City of Hope Medical Center	Phase 2
Recruiting	Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refracto NCT06649812	National Cancer Institute (NCI)	Phase 2
Recruiting	Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma NCT06536049	Yazeed Sawalha	Phase 1 / Phase 2
Recruiting	Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patien NCT05821088	David Bond, MD	Phase 2
Active Not Recruiting	TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lym NCT05507541	Mayo Clinic	Phase 2
Withdrawn	Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Rec NCT05228249	Fred Hutchinson Cancer Center	Phase 1
Recruiting	Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma NCT05755087	Lapo Alinari	Phase 1
Withdrawn	Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphom NCT04285268	Rutgers, The State University of New Jersey	Phase 2
Active Not Recruiting	Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lympho NCT03038672	National Cancer Institute (NCI)	Phase 2
Terminated	huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Ac NCT03103971	Fred Hutchinson Cancer Center	Phase 1
Recruiting	Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lympho NCT03136146	M.D. Anderson Cancer Center	Phase 2
Completed	Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas NCT01897012	National Cancer Institute (NCI)	Phase 1